Literature DB >> 9176531

Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection.

R J Davies1, Z C Traill, F V Gleeson.   

Abstract

BACKGROUND: Standard treatment for pleural infection includes catheter drainage and antibiotics. Tube drainage often fails if the fluid is loculated by fibrinous adhesions when surgical drainage is needed. Streptokinase may aid the process of pleural drainage, but there have been no controlled trials to assess its efficacy.
METHODS: Twenty four patients with infected community acquired parapneumonic effusions were studied. All had either frankly purulent/culture or Gram stain positive pleural fluid (13 cases; 54%) or fluid which fulfilled the biochemical criteria for pleural infection. Fluid was drained with a 14F catheter. The antibiotics used were cefuroxime and metronidazole or were guided by culture. Subjects were randomly assigned to receive intrapleural streptokinase, 250,000 i.u. daily, or control saline flushes for three days. The primary end points related to the efficacy of pleural drainage--namely, the volume of pleural fluid drained and the chest radiographic response to treatment. Other end points were the number of pleural procedures needed and blood indices of inflammation.
RESULTS: The streptokinase group drained more pleural fluid both during the days of streptokinase/control treatment (mean (SD) 391 (200) ml versus 124 (44) ml; difference 267 ml, 95% confidence interval (CI) 144 to 390; p < .001) and overall (2564 (1663) ml, 95% CI 465 to 2545; p < 0.01). They showed greater improvement on the chest radiograph at discharge, measured as the fall in the maximum dimension of the pleural collection (6.0 (2.7) cm versus 3.4 (2.7) cm; difference 2.9 cm, 95% CI 0.3 to 4.4; p < 0.05) and the overall reduction in pleural fluid collection size (p < 0.05, two-tailed Fisher's exact test). Systemic fibrinolysis and bleeding complications did not occur. Surgery was required by three control patients but none in the streptokinase group.
CONCLUSIONS: Intrapleural streptokinase probably aids the treatment of pleural infections by improving pleural drainage without causing systemic fibrinolysis or local haemorrhage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176531      PMCID: PMC1758567          DOI: 10.1136/thx.52.5.416

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  21 in total

1.  Use of purified streptokinase in empyema and hemothorax.

Authors:  R W Aye; D P Froese; L D Hill
Journal:  Am J Surg       Date:  1991-05       Impact factor: 2.565

2.  Treatment of total hyphemas with urokinase.

Authors:  D M Leet
Journal:  Am J Ophthalmol       Date:  1977-07       Impact factor: 5.258

3.  Pleural fluid pH in parapneumonic effusions.

Authors:  D E Potts; D C Levin; S A Sahn
Journal:  Chest       Date:  1976-09       Impact factor: 9.410

Review 4.  Management of complicated parapneumonic effusions.

Authors:  S A Sahn
Journal:  Am Rev Respir Dis       Date:  1993-09

5.  Treatment of empyema thoracis.

Authors:  D K Kaplan
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

6.  The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia.

Authors:  D A Taryle; D E Potts; S A Sahn
Journal:  Chest       Date:  1978-08       Impact factor: 9.410

7.  Abnormalities of pathways of fibrin turnover in the human pleural space.

Authors:  S Idell; W Girard; K B Koenig; J McLarty; D S Fair
Journal:  Am Rev Respir Dis       Date:  1991-07

8.  Role of streptokinase in the treatment of acute loculated parapneumonic pleural effusions and empyema.

Authors:  D Bouros; S Schiza; P Panagou; J Drositis; N Siafakas
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

9.  Empyema of the thorax in adults. Etiology, microbiologic findings, and management.

Authors:  I Alfageme; F Muñoz; N Peña; S Umbría
Journal:  Chest       Date:  1993-03       Impact factor: 9.410

10.  Parapneumonic effusions.

Authors:  R W Light; W M Girard; S G Jenkinson; R B George
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

View more
  32 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Video-assisted thoracic surgery in the treatment of pleural empyema.

Authors:  L Solaini; F Prusciano; P Bagioni
Journal:  Surg Endosc       Date:  2006-11-21       Impact factor: 4.584

3.  Intrapleural streptokinase for pleural infection.

Authors:  Demosthenes Bouros; Katerina M Antoniou; Richard W Light
Journal:  BMJ       Date:  2006-01-21

4.  Empyema: the use of broad range 16S rDNA PCR for pathogen detection.

Authors:  S Saglani; K A Harris; C Wallis; J C Hartley
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

5.  Intrapleural streptokinase for pleural infection.

Authors:  Nick Maskell; Andrew Nunn; Robert J O Davies
Journal:  BMJ       Date:  2006-03-04

Review 6.  Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection.

Authors:  Francesco Piccolo; Natalia Popowicz; Donny Wong; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 7.  A Primer on the Management of Pleural Effusions.

Authors:  William Bremer; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

8.  Intrapleural streptokinase treatment in children with empyema.

Authors:  Metin Aydoğan; Ayşen Aydoğan; Ayla Ozcan; Melih Tugay; Ayse Sevim Gokalp; Emin Sami Arisoy
Journal:  Eur J Pediatr       Date:  2007-08-21       Impact factor: 3.183

9.  Empyema thoracis.

Authors:  Ala Eldin H Ahmed; Tariq E Yacoub
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2010-06-17

10.  Update on pleural diseases--2007.

Authors:  Ayman Bishay; Suhail Raoof; Adebayo Esan; Arthur Sung; Siraj Wali; Leonard Y Lee; Liziamma George; Anthony Saleh; Michael Baumann
Journal:  Ann Thorac Med       Date:  2007-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.